Effect of oxyntomodulin, glucagon, GLP-1, and combined glucagon +GLP-1 infusion on food intake, appetite, and resting energy expenditure

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 12, 2015, Pages 4541-4552

  Bagger, Jonatan Ising ^a   Holst, Jens Juul ^a   Hartmann, Bolette ^a   Andersen, Birgitte ^b   Knop, Filip Krag ^a   Vilsbøll, Tina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; OXYNTOMODULIN; ANALGESIC AGENT; PARACETAMOL;

ADULT; APPETITE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTING ENERGY EXPENDITURE; STEADY STATE; STOMACH EMPTYING; ADOLESCENT; BLOOD; DRUG EFFECTS; DRUG INTERACTION; EATING; ENERGY METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; PHYSIOLOGY; REST; YOUNG ADULT;

ACETAMINOPHEN; ADOLESCENT; ADULT; ANALGESICS, NON-NARCOTIC; APPETITE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; EATING; ENERGY METABOLISM; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFUSIONS, INTRAVENOUS; MALE; OXYGEN CONSUMPTION; OXYNTOMODULIN; REST; YOUNG ADULT;

EID: 84951066421     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2335     Document Type: Article

References (40)

1. Schjoldager BT, Baldissera FG, Mortensen PE, Holst JJ, Christiansen J. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest. 1988;18(5):499-503.
2. Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology. 2001;142(10):4244-4250.
3. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a doubleblind, randomized, controlled trial. Diabetes. 2005;54(8):2390-2395.
4. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes. 2006; 2005 30(12):1729-1736.
5. Gros L, Thorens B, Bataille D, Kervran A. Glucagon-like peptide- 1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology. 1993;133(2):631-638.
6. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV. Oxyntomodulin (glicentin-(33- 69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept. 1988;21(1-2):151-166.
7. Holst JJ. Enteroglucagon. Annu Rev Physiol. 1997;59:257-271.
8. Holst JJ. Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin- current status. Gastroenterology. 1983;84(6): 1602-1613.
9. Holst JJ. Evidence that enteroglucagon (II) is identical with the Cterminal sequence (residues 33-69) of glicentin. Biochem J. 1982; 207(3):381-388.
10. Druce MR, Minnion JS, Field BCT, et al. Investigation of structureactivity relationships of Oxyntomodulin (Oxm) usingOxmanalogs. Endocrinology. 2009;150(4):1712-1722.
11. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 Pt 1):E981-E988.
12. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616.
13. Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord. 2001;25(6):781-792.
14. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824-830.
15. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 2004;127(2):546-558.
16. Penick SB, Hinkle LE Jr. Depression of food intake induced in healthy subjects by glucagon. N Engl J Med. 1961;264:893-897.
17. Schulman JL, Carleton JL, Whitney G, Whitehorn JC. Effect of glucagon on food intake and body weight in man. J Appl Physiol. 1957;11(3):419-421.
18. Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol. 1992;262(6 Pt 2):R975-R980.
19. Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258-2266.
20. Kosinski JR, Hubert J, Carrington PE, et al. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obes (Silver Spring Md). 2012;20(8):1566-1571.
21. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000; 24(1):38-48.
22. Gregersen NT, Flint A, Bitz C, Blundell JE, Raben A, Astrup A. Reproducibility and power of ad libitum energy intake assessed by repeated single meals. Am J Clin Nutr. 2008;87(5):1277-1281.
23. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagonlike peptide I in humans. Diabetes. 1994;43(4):535-539.
24. Albrechtsen NJW, Hartmann B, Veedfald S, et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia. 2014;57(9):1919- 1926.
25. Sloth B, Due A, LarsenTM,Holst JJ, Heding A, Astrup A. The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period. Br J Nutr. 2009;101(12):1846-1858.
26. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer; 2000.
27. VanCauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992;41(3):368-377.
28. Kjems LL, Christiansen E, Vølund A, Bergman RN, Madsbad S. Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes. 2000;49(4):580-588.
29. Kjems LL, Vølund A, Madsbad S. Quantification of-cell function during IVGTT in type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods. Diabetologia. 2001; 44(10):1339-1348.
30. D?Alessio DA, Kavle EC, Mozzoli MA, et al. Thermic effect of food in lean and obese men. J Clin Invest. 1988;81(6):1781-1789.
31. Shalev A, Holst JJ, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest. 1997;27(1):10-16.
32. Christin L, Nacht CA, Vernet O, Ravussin E, Jèquier E, Acheson KJ. Insulin. Its role in the thermic effect of glucose. J Clin Invest. 1986; 77(6):1747-1755.
33. Tan TM, Field BCT, McCullough KA, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62(4):1131-1138.
34. Schmidt JB, Gregersen NT, Pedersen SD, et al. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men. Am J Physiol Endocrinol Metab. 2014;306(11): E1248-E1256.
35. Harder H, Nielsen L, Thi TDT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27(8):1915-1921.
36. Van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2014;38(6):784-793.
37. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58(1):250-259.
38. Taylor I, Duthie HL, Cumberland DC, Smallwood R. Glucagon and the colon. Gut. 1975;16(12):973-978.
39. Dotevall G, Kock NG. The effect of glucagon on intestinal motility in man. Gastroenterology. 1963;45:364-367.
40. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003;88(10):4696-4701.